
    
      This study is a single-arm, multicenter, exploratory phase II study to observe the efficacy
      and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in
      patients with advanced ovarian cancer. The primary end point are progression free survival;
      the secondary end points include objective response rate, disease control rate, overall
      survival and safety. The subjects in this study: patients with newly diagnosed advanced (FIGO
      stage III-IV) ovarian cancer, including histologically or pathologically confirmed high-grade
      serous ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
    
  